Citation: Gerardo Abenes, Fenyong Liu. Pathogenetic Consequences of Cytomegalovirus-Host Co-evolution .VIROLOGICA SINICA, 2008, 23(6) : 438-448.  http://dx.doi.org/10.1007/s12250-008-3003-2

Pathogenetic Consequences of Cytomegalovirus-Host Co-evolution

  • Corresponding author: Fenyong Liu, liu_fy@uclink4.berkeley.edu
  • Received Date: 09 September 2008
    Accepted Date: 24 September 2008
    Available online: 01 December 2008

    Fund Project: This work was, in part, supported by US Public Health Service DE014145This work was, in part, supported by US Public Health Service AI041927This work was, in part, supported by US Public Health Service AI050468This work was, in part, supported by US Public Health Service DE016813

  • Co-evolution has been shown to result in an adaptive reciprocal modification in the respective behaviors of interacting populations over time. In the case of host-parasite co-evolution, the adaptive behavior is most evident from the reciprocal change in fitness of host and parasite-manifested in terms of pathogen survival versus host resistance. Cytomegaloviruses and their hosts represent a pairing of populations that has co-evolved over hundreds of years. This review explores the pathogenetic consequences emerging from the behavioral changes caused by co-evolutionary forces on the virus and its host.

  • 加载中
    1. Adler S P, Marshall B. 2007. Cytomegalovirus in-fections. Pediatr Rev, 28: 92-100.
        doi: 10.1542/pir.28-3-92

    2. Ahn K, Angulo A, Ghazal P, et al. 1996. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci USA, 93: 10990-10995.
        doi: 10.1073/pnas.93.20.10990

    3. Ahn K, Gruhler A, Galocha B, et al. 1997. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity, 6: 613-621.
        doi: 10.1016/S1074-7613(00)80349-0

    4. Arase H, Mocarski E S, Campbell A E, et al. 2002. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science, 296: 1323-1326.
        doi: 10.1126/science.1070884

    5. Askin D F. 2004. Intrauterine infections. Neonatal Netw, 23: 23-30.
        doi: 10.1891/0730-0832.23.5.23

    6. Atreya I, Atreya R, Neurath M F. 2008. NF-kappaB in inflammatory bowel disease. J Intern Med, 263:591-596.
        doi: 10.1111/j.1365-2796.2008.01953.x

    7. Bale J F. 2002. Congenital infections. Neurol Clin, 20:1039-1060.
        doi: 10.1016/S0733-8619(02)00014-2

    8. Bason C, Corrocher R, Lunardi C, et al. 2003. Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis. Lancet, 362: 1971-1977.
        doi: 10.1016/S0140-6736(03)15016-7

    9. Basta S, Bennink J R. 2003. A survival game of hide and seek: cytomegaloviruses and MHC class Ⅰ antigen presentation pathways. Viral Immunol, 16: 231-242.
        doi: 10.1089/088282403322396064

    10. Bauer D, Tampe R. 2002. Herpes viral proteins blocking the transporter associated with antigen processing TAP--from genes to function and structure. Curr Top Micro-biol Immunol, 269: 87-99.

    11. Bego M G, St Jeor S. 2006. Human cytomegalovirus infection of cells of hematopoietic origin: HCMV-induced immunosuppression, immune evasion, and latency. Exp Hematol, 34: 555-570.
        doi: 10.1016/j.exphem.2005.11.012

    12. Beisser P S, Goh C S, Cohen F E, et al. 2002. Viral chemokine receptors and chemokines in human cytomega-lovirus trafficking and interaction with the immune system. CMV chemokine receptors. Curr Top Microbiol Im-munol, 269: 203-34.

    13. Bentz G L, Yurochko A D. 2008. Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and beta1 and beta3 integrins. Proc Natl Acad Sci USA, 105: 5531-5536.
        doi: 10.1073/pnas.0800037105

    14. Boomker J M, de Jong E K, de Leij L F, et al. 2006. Chemokine scavenging by the human cytomegalovirus chemokine decoy receptor US28 does not inhibit monocyte adherence to activated endothelium. Antiviral Res, 69: 124-127.
        doi: 10.1016/j.antiviral.2005.11.003

    15. Boomker J M, van Luyn M J, The T H, et al. 2005. US28 actions in HCMV infection: lessons from a versa-tile hijacker. Rev Med Virol, 15: 269-282.
        doi: 10.1002/(ISSN)1099-1654

    16. Braud V M, Tomasec P, Wilkinson G W. 2002. Viral evasion of natural killer cells during human cytomega-lovirus infection. Curr Top Microbiol Immunol, 269: 117-129.

    17. Bryant P, Morley C, Garland S, et al. 2002. Cytomega-lovirus transmission from breast milk in premature babies: does it matter? Arch Dis Child Fetal Neonatal Ed, 87: F75-77.
        doi: 10.1136/fn.87.2.F75

    18. Candore G, Balistreri C R, Colonna-Romano G, et al. 2008. Immunosenescence and anti-immunosenescence therapies: the case of probiotics. Rejuvenation Res, 11: 425-432.
        doi: 10.1089/rej.2008.0662

    19. Chalupny N J, Rein-Weston A, Dosch S, et al. 2006. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun, 346: 175-181.
        doi: 10.1016/j.bbrc.2006.05.092

    20. Chang M, Pan M R, Chen D Y, et al. 2006. Human cytomegalovirus pp65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice. Clin Exp Immunol, 143: 167-179.
        doi: 10.1111/cei.2006.143.issue-1

    21. Chapman T L, Heikeman A P, Bjorkman P J. 1999. The inhibitory receptor LIR-1 uses a common binding interac-tion to recognize class Ⅰ MHC molecules and the viral homolog UL18. Immunity, 11: 603-613.
        doi: 10.1016/S1074-7613(00)80135-1

    22. Cosman D, Mullberg J, Sutherland C L, et al. 2001. ULBPs, novel MHC class Ⅰ-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity, 14: 123-133.
        doi: 10.1016/S1074-7613(01)00095-4

    23. Criscuoli V, Rizzuto M R, Cottone M. 2006. Cytomega-lovirus and inflammatory bowel disease: is there a link? World J Gastroenterol, 12: 4813-4818.

    24. Damato E G, Winnen C W. 2002. Cytomegalovirus infection: perinatal implications. J Obstet Gynecol Neo-natal Nurs, 31: 86-92.
        doi: 10.1111/j.1552-6909.2002.tb00026.x

    25. Davison A J, Dolan A, Akter P, et al. 2003. The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J Gen Virol, 84: 17-28.
        doi: 10.1099/vir.0.18606-0

    26. DeFilippis V R. 2007. Induction and evasion of the type Ⅰ interferon response by cytomegaloviruses. Adv Exp Med Biol, 598:309-24.
        doi: 10.1007/978-0-387-71767-8

    27. Diaz F, Urkijo J C, Mendoza F, et al. 2006. Systemic lupus erythematosus associated with acute cytomega-lovirus infection. J Clin Rheumatol, 12: 263-264.
        doi: 10.1097/01.rhu.0000239832.74804.17

    28. Dimitroulia E, Spanakis N, Konstantinidou A E, et al. 2006. Frequent detection of cytomegalovirus in the in-testine of patients with inflammatory bowel disease. Inflamm Bowel Dis, 12: 879-884.
        doi: 10.1097/01.mib.0000231576.11678.57

    29. Dugan G E, Hewitt E W. 2008. Structural and Func-tional Dissection of the Human Cytomegalovirus Immune Evasion Protein US6. J Virol, 82: 3271-3282.
        doi: 10.1128/JVI.01705-07

    30. Dunn C, Chalupny N J, Sutherland C L, et al. 2003. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med, 197: 1427-1439.
        doi: 10.1084/jem.20022059

    31. Dunn W, Chou C, Li H, et al. 2003. Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci USA, 100: 14223-14228.
        doi: 10.1073/pnas.2334032100

    32. Editorial Comments. 2004. Cytomegalovirus. Am J Transplant, 4 Suppl 10:51-58.

    33. Emery V C. 2001. Cytomegalovirus and the aging popu-lation. Drugs Aging, 18: 927-933.
        doi: 10.2165/00002512-200118120-00004

    34. Emery V C. 2001. Investigation of CMV disease in immunocompromised patients. J Clin Pathol, 54: 84-88.
        doi: 10.1136/jcp.54.2.84

    35. Franceschi C. 2007. Inflammaging as a major charac-teristic of old people: can it be prevented or cured? Nutr Rev, 65: S173-176.

    36. Franceschi C, Bonafe M. 2003. Centenarians as a model for healthy aging. Biochem Soc Trans 31: 457-61.
        doi: 10.1042/bst0310457

    37. Froberg M K. 2004. Review: CMV escapes! Ann Clin Lab Sci, 34: 123-130.

    38. Gewurz B E, Gaudet R, Tortorella D, et al. 2001. Antigen presentation subverted: Structure of the human cytomegalovirus protein US2 bound to the class Ⅰ mo-lecule HLA-A2. Proc Natl Acad Sci USA, 98: 6794-6799.
        doi: 10.1073/pnas.121172898

    39. Giunta S. 2006. Is inflammaging an auto[innate] immunity subclinical syndrome? Immun Ageing, 3: 12.
        doi: 10.1186/1742-4933-3-12

    40. Gold E, Nankervis G A. 1976. Cytomegalovirus. In: Viral infections of humans: epidemiology and control (Evans A S ed.), Plenum Press: New York, p 143-161.

    41. Goldmacher V S. 2005. Cell death suppression by cytomegaloviruses. Apoptosis, 10: 251-265.
        doi: 10.1007/s10495-005-0800-z

    42. Goldmacher V S. 2002. vMIA, a viral inhibitor of apo-ptosis targeting mitochondria. Biochimie, 84: 177-185.
        doi: 10.1016/S0300-9084(02)01367-6

    43. Hengel H, Koopmann J O, Flohr T, et al. 1997. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter.Immunity, 6: 623-632.
        doi: 10.1016/S1074-7613(00)80350-7

    44. Hommes D W, Sterringa G, van Deventer S J, et al. 2004. The pathogenicity of cytomegalovirus in inflam-matory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis, 10: 245-250.
        doi: 10.1097/00054725-200405000-00011

    45. Hooper M, Kallas E G, Coffin D, et al. 1999. Cytomega-lovirus seropositivity is associated with the expansion of CD4+CD28- and CD8+CD28- T cells in rheumatoid arthritis. J Rheumatol, 26: 1452-1457.

    46. Hrycek A, Kusmierz D, Mazurek U, et al. 2005. Human cytomegalovirus in patients with systemic lupus ery-thematosus. Autoimmunity, 38: 487-491.
        doi: 10.1080/08916930500285667

    47. Hussein K, Hayek T, Yassin K, et al. 2006. Acute cytomegalovirus infection associated with the onset of inflammatory bowel disease. Am J Med Sci, 331: 40-43.
        doi: 10.1097/00000441-200601000-00012

    48. Jarvis M A, Borton J A, Keech A M, et al. 2006. Human cytomegalovirus attenuates interleukin-1beta and tumor necrosis factor alpha proinflammatory signaling by inhibition of NF-kappaB activation. J Virol, 80: 5588-5598.
        doi: 10.1128/JVI.00060-06

    49. Jarvis M A, Nelson J A. 2002. Human cytomegalovirus persistence and latency in endothelial cells and macrop-hages.Curr Opin Microbiol, 5:403-407.
        doi: 10.1016/S1369-5274(02)00334-X

    50. Jarvis M A, Nelson J A. 2002. Mechanisms of human cytomegalovirus persistence and latency. Front Biosci, 7:d1575-1582.
        doi: 10.2741/A862

    51. Jenkins C, Abendroth A, Slobedman B. 2004. A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection. J Virol, 78: 1440-1447.
        doi: 10.1128/JVI.78.3.1440-1447.2004

    52. Johnson D C, Hegde N R. 2002. Inhibition of the MHC class Ⅱ antigen presentation pathway by human cytomega-lovirus. Curr Top Microbiol Immunol, 269: 101-115.

    53. Jones T R, Wiertz E J, Sun L, et al. 1996. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class Ⅰ heavy chains. Proc Natl Acad Sci USA, 93: 11327-11333.
        doi: 10.1073/pnas.93.21.11327

    54. Jurak I, Brune W. 2006. Induction of apoptosis limits cytomegalovirus cross-species infection. Embo J, 25: 2634-2642.
        doi: 10.1038/sj.emboj.7601133

    55. Kanapeckiene V, Kalibatas J, Redaitiene E, et al. 2007. The association between cytomegalovirus infection and aging process. Medicina (Kaunas), 43: 419-424.

    56. Kavanagh D G, Hill A B. 2001. Evasion of cytotoxic T lymphocytes by murine cytomegalovirus. Semin Im-munol, 13: 19-26.
        doi: 10.1006/smim.2001.0292

    57. Kerrey B T, Morrow A, Geraghty S, et al. 2006. Breast milk as a source for acquisition of cytomegalovirus (HCMV) in a premature infant with sepsis syndrome: detection by real-time PCR. J Clin Virol, 35: 313-316.
        doi: 10.1016/j.jcv.2005.09.013

    58. Khan N. 2007. The immunological burden of human cytomegalovirus infection. Arch Immunol Ther Exp (Warsz), 55: 299-308.
        doi: 10.1007/s00005-007-0037-3

    59. Khan N, Hislop A, Gudgeon N, et al. 2004. Herpes-virus-specific CD8 T cell immunity in old age: cytomega-lovirus impairs the response to a coresident EBV infection. J Immunol, 173: 7481-7489.
        doi: 10.4049/jimmunol.173.12.7481

    60. Khan N, Shariff N, Cobbold M, et al. 2002. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol, 169: 1984-1992.
        doi: 10.4049/jimmunol.169.4.1984

    61. Khoshnevis M, Tyring S K. 2002. Cytomegalovirus infections. Dermatol Clin, 20:291-299, vii.
        doi: 10.1016/S0733-8635(01)00007-9

    62. Kinney J S, Onorato I M, Stewart J A, et al. 1985. Cytomegaloviral infection and disease. J Infect Dis, 151: 772-774.
        doi: 10.1093/infdis/151.5.772

    63. Kojima T, Watanabe T, Hata K, et al. 2006. Cytomega-lovirus infection in ulcerative colitis. Scand J Gastroen-terol, 41: 706-711.
        doi: 10.1080/00365520500408584

    64. Koutouzov S, Jeronimo A L, Campos H, et al. 2004. Nucleosomes in the pathogenesis of systemic lupus ery-thematosus.Rheum Dis Clin North Am, 30: 529-558, ix.
        doi: 10.1016/j.rdc.2004.04.001

    65. Krmpotic A, Bubic I, Polic B, et al. 2003. Pathogenesis of murine cytomegalovirus infection. Microbes Infect, 5: 1263-1277.
        doi: 10.1016/j.micinf.2003.09.007

    66. Landolfo S, Gariglio M, Gribaudo G, et al. 2003. The human cytomegalovirus. Pharmacol Ther, 98: 269-297.
        doi: 10.1016/S0163-7258(03)00034-2

    67. Lehner P J, Karttunen J T, Wilkinson G W, et al. 1997. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc Natl Acad Sci USA, 94: 6904-6909.
        doi: 10.1073/pnas.94.13.6904

    68. Lenac T, Arapovic J, Traven L, et al. 2008. Murine cytomegalovirus regulation of NKG2D ligands. Med Microbiol Immunol, 197: 159-166.
        doi: 10.1007/s00430-008-0080-7

    69. Lin A, Xu H, Yan W. 2007. Modulation of HLA expres-sion in human cytomegalovirus immune evasion. Cell Mol Immunol, 4: 91-98.

    70. Lodoen M B, Abenes G, Umamoto S, et al. 2004. The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions. J Exp Med, 200: 1075-1081.
        doi: 10.1084/jem.20040583

    71. Loenen W A, Bruggeman C A, Wiertz E J. 2001. Im-mune evasion by human cytomegalovirus: lessons in immunology and cell biology. Semin Immunol, 13: 41-49.
        doi: 10.1006/smim.2001.0294

    72. Lunardi C, Bason C, Corrocher R, et al. 2005. Induction of endothelial cell damage by hCMV molecular mimicry. Trends Immunol, 26: 19-24.
        doi: 10.1016/j.it.2004.10.009

    73. Lunardi C, Bason C, Navone R, et al. 2000. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med, 6: 1183-1186.
        doi: 10.1038/80533

    74. Lunardi C, Dolcino M, Peterlana D, et al. 2006. Antibodies against human cytomegalovirus in the patho-genesis of systemic sclerosis: a gene array approach. PLoS Med, 3: e2.

    75. Lunardi C, Dolcino M, Peterlana D, et al. 2007. Endothelial cells' activation and apoptosis induced by a subset of antibodies against human cytomegalovirus: relevance to the pathogenesis of atherosclerosis. PLoS ONE, 2: e473
        doi: 10.1371/journal.pone.0000473

    76. Mattey D L, Dawes P T, Nixon N B, et al. 2004. Increased levels of antibodies to cytokeratin 18 in patients with rheumatoid arthritis and ischaemic heart disease. Ann Rheum Dis, 63: 420-425.
        doi: 10.1136/ard.2003.008011

    77. McCormick A L. 2008. Control of apoptosis by human cytomegalovirus. Curr Top Microbiol Immunol, 325: 281-295.

    78. Mehraein Y, Lennerz C, Ehlhardt S, et al. 2004. Latent Epstein-Barr virus (EBV) infection and cytomegalovirus (CMV) infection in synovial tissue of autoimmune chronic arthritis determined by RNA-and DNA-in situ hybridization. Mod Pathol, 17: 781-789.
        doi: 10.1038/modpathol.3800119

    79. Mocarski E S. 2002. Immunomodulation by cytomega-loviruses: manipulative strategies beyond evasion. Trends Microbiol, 10:332-339.
        doi: 10.1016/S0966-842X(02)02393-4

    80. Mocarski E S. Courcelle, C. T. Cytomegalovirus and their replication, In: Fields' Virology (Knipe D M, Howley P M, ed. ), Lippincott : Philadelphia, p2629-2673.

    81. Murphy E, Rigoutsos I, Shibuya T, et al. 2003. Reevaluation of human cytomegalovirus coding potential. Proc Natl Acad Sci USA, 100: 13585-13590.
        doi: 10.1073/pnas.1735466100

    82. Murphy E, Yu D, Grimwood J, et al. 2003. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci USA, 100: 14976-14981.
        doi: 10.1073/pnas.2136652100

    83. Namboodiri A M, Rocca K M, Kuwana M, et al. 2006. Antibodies to human cytomegalovirus protein UL83 in systemic sclerosis. Clin Exp Rheumatol, 24: 176-178.

    84. Noyola D E, Valdez-Lopez B H, Hernandez-Salinas A E, et al. 2005. Cytomegalovirus excretion in children attending day-care centers. Arch Med Res, 36: 590-593.
        doi: 10.1016/j.arcmed.2005.03.045

    85. Pandey J P. 2004. Immunoglobulin GM genes and IgG antibodies to cytomegalovirus in patients with systemic sclerosis. Clin Exp Rheumatol, 22: S35-7.

    86. Pass R F. 2001. Cytomegalovirus, In: Fields' Virology (Knipe D M, Howley P M ed. ), Lippincott: Philadelphia, p2675-2705.

    87. Pass R F. 2002. Cytomegalovirus infection. Pediatr Rev, 23: 163-170.
        doi: 10.1542/pir.23-5-163

    88. Pass R F. 1985. Epidemiology and transmission of cytomegalovirus. J Infect Dis, 152: 243-248.
        doi: 10.1093/infdis/152.2.243

    89. Pawelec G, Gouttefangeas C. 2006. T-cell dysregulation caused by chronic antigenic stress: the role of CMV in immunosenescence? Aging Clin Exp Res, 18: 171-173.
        doi: 10.1007/BF03327436

    90. Pawelec G, Larbi A. 2008. Immunity and ageing in man: Annual Review 2006/2007. Exp Gerontol, 43: 34-38.

    91. Peichl P, Scriba M, Haberhauer G, et al. 1988. Selective binding of rheumatoid factors to antigen structures of cytomegalovirus (CMV). Scand J Rheumatol, Suppl 75: 117-122.

    92. Pereira L, Maidji E, McDonagh S, et al. 2005. Insights into viral transmission at the uterine-placental interface. Trends Microbiol, 13: 164-174.
        doi: 10.1016/j.tim.2005.02.009

    93. Plachter B, Sinzger C, Jahn G. 1996. Cell types in-volved in replication and distribution of human cytomega-lovirus. Adv Virus Res, 46: 195-261.
        doi: 10.1016/S0065-3527(08)60073-1

    94. Rafailidis P I, Mourtzoukou E G, Varbobitis I C, et al. 2008. Severe cytomegalovirus infection in apparently im-munocompetent patients: a systematic review. Virol J, 5: 47.
        doi: 10.1186/1743-422X-5-47

    95. Rahbar A, Bostrom L, Soderberg-Naucler C. 2006. Detection of cytotoxic CD13-specific autoantibodies in sera from patients with ulcerative colitis and Crohn's disease. J Autoimmun, 26: 155-164.
        doi: 10.1016/j.jaut.2006.02.003

    96. Rajagopalan S, Long E O. 2005. Viral evasion of NK-cell activation. Trends Immunol, 26: 403-405.
        doi: 10.1016/j.it.2005.06.008

    97. Randolph-Habecker J R, Rahill B, Torok-Storb B, et al. 2002. The expression of the cytomegalovirus chemokine receptor homolog US28 sequesters biologically active CC chemokines and alters IL-8 production. Cytokine, 19: 37-46.
        doi: 10.1006/cyto.2002.0874

    98. Rawlinson W D, Farrell H E, Barrell B G. 1996. Analysis of the complete DNA sequence of murine cytomegalovirus. J Virol, 70: 8833-8849.

    99. Reddehase M J, Podlech J, Grzimek N K. 2002. Mouse models of cytomegalovirus latency: overview. J Clin Virol, 25 Suppl 2:S23-36.

    100. Reeves M B, Lehner P J, Sissons J G, et al. 2005. An in vitro model for the regulation of human cytomegalovirus latency and reactivation in dendritic cells by chromatin remodelling. J Gen Virol, 86: 2949-2954.
        doi: 10.1099/vir.0.81161-0

    101. Reeves M B, MacAry P A, Lehner P J, et al. 2005. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc Natl Acad Sci USA, 102: 4140-4145.
        doi: 10.1073/pnas.0408994102

    102. Reynolds D W, Stagno S, Alford C A. 1981. Chronic congenital and perinatal infections, In: Neonatal pathop-hysiolaogy and management in the newborn (Avery G B, ed. ). Lippincott : Philadelphia, p748-789.

    103. Rezania D, Ouban A, Marcet J, et al. 2007. CMV colitis mimicking recurrent inflammatory bowel disease: report of three cases. Am Surg, 73: 58-61.

    104. Roback J D. 2002. CMV and blood transfusions. Rev Med Virol, 12: 211-219.
        doi: 10.1002/(ISSN)1099-1654

    105. Robinson J. 2001. Infectious diseases in schools and child care facilities. Pediatr Rev, 22: 39-46.
        doi: 10.1542/pir.22-2-39

    106. Ross S A, Boppana S B. 2005. Congenital cytomega-lovirus infection: outcome and diagnosis. Semin Pediatr Infect Dis, 16: 44-49.
        doi: 10.1053/j.spid.2004.09.011

    107. Sansoni P, Vescovini R, Fagnoni F, et al. 2008. The immune system in extreme longevity. Exp Gerontol, 43: 61-65.
        doi: 10.1016/j.exger.2007.06.008

    108. Scalzo A A, Corbett A J, Rawlinson W D, et al. 2007. The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol Cell Biol, 85: 46-54.
        doi: 10.1038/sj.icb.7100013

    109. Schleiss M R. 2003. Vertically transmitted herpesvirus infections. Herpes, 10:4-11.

    110. Sekigawa I, Nawata M, Seta N, et al. 2002. Cytomega-lovirus infection in patients with systemic lupus ery-thematosus.Clin Exp Rheumatol, 20: 559-564.

    111. Sinclair J. 2008. Human cytomegalovirus: Latency and reactivation in the myeloid lineage. J Clin Virol, 41: 180-185.
        doi: 10.1016/j.jcv.2007.11.014

    112. Sinclair J, Sissons P. 2006. Latency and reactivation of human cytomegalovirus. J Gen Virol, 87: 1763-1779.
        doi: 10.1099/vir.0.81891-0

    113. Sinzger C, Jahn G. 1996. Human cytomegalovirus cell tropism and pathogenesis. Intervirology, 39: 302-319.
        doi: 10.1159/000150502

    114. Sissons J G, Bain M, Wills M R. 2002. Latency and reactivation of human cytomegalovirus. J Infect, 44: 73-77.
        doi: 10.1053/jinf.2001.0948

    115. Skaletskaya A, Bartle L M, Chittenden T, et al. 2001. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc Natl Acad Sci USA, 98: 7829-7834.
        doi: 10.1073/pnas.141108798

    116. Smith H R, Heusel J W, Mehta I K, et al. 2002. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci USA, 99: 8826-8831.
        doi: 10.1073/pnas.092258599

    117. Smith M G. 1956. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease. Proc Soc Exp Biol Med, 92: 424-440.
        doi: 10.3181/00379727-92-22498

    118. Smith M G. 1954. Propagation of salivary gland virus of the mouse in tissue cultures. Proc Soc Exp Biol Med, 86: 435-440.
        doi: 10.3181/00379727-86-21123

    119. Soderberg-Naucler C, Fish K N, Nelson J A. 1997. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell, 91: 119-126.
        doi: 10.1016/S0092-8674(01)80014-3

    120. Soderberg-Naucler C, Streblow D N, Fish K N, et al. 2001. Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent. J Virol, 75: 7543-7554.
        doi: 10.1128/JVI.75.16.7543-7554.2001

    121. Stahl H D, Hubner B, Seidl B, et al. 2000. Detection of multiple viral DNA species in synovial tissue and fluid of patients with early arthritis. Ann Rheum Dis, 59: 342-346.
        doi: 10.1136/ard.59.5.342

    122. Staras S A, Dollard S C, Radford K W, et al. 2006. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis, 43: 1143-1151.
        doi: 10.1086/508173

    123. Streblow D N, Dumortier J, Moses A V, et al. 2008. Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing. Curr Top Microbiol Immunol, 325: 397-415.

    124. Sutherland C L, Chalupny N J, Schooley K, et al. 2002. UL16-binding proteins, novel MHC class Ⅰ-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol, 168: 671-679.
        doi: 10.4049/jimmunol.168.2.671

    125. Tang Q, Maul G G. 2006. Mouse cytomegalovirus crosses the species barrier with help from a few human cytomegalovirus proteins. J Virol, 80: 7510-7521.
        doi: 10.1128/JVI.00684-06

    126. Terhune S, Torigoi E, Moorman N, et al. 2007. Human cytomegalovirus UL38 protein blocks apoptosis. J Virol, 81: 3109-3123.
        doi: 10.1128/JVI.02124-06

    127. Thompson J N. 1994. The Coevolutionary Process. University of Chicago Press: Chicago, USA.

    128. Tsuchiya N, Murayama T, Yoshinoya S, et al. 1993. Antibodies to human cytomegalovirus 65-kilodalton Fc binding protein in rheumatoid arthritis: idiotypic mimicry hypothesis of rheumatoid factor production. Autoim-munity, 15: 39-48.
        doi: 10.3109/08916939309004837

    129. Vancikova Z, Dvorak P. 2001. Cytomegalovirus in-fection in immunocompetent and immunocompromised individuals--a review. Curr Drug Targets Immune Endocr Metabol Disord, 1: 179-187.
        doi: 10.2174/1568005310101020179

    130. Vasto S, Colonna-Romano G, Larbi A et al. 2007. Role of persistent CMV infection in configuring T cell immunity in the elderly.Immun Ageing, 4: 2.
        doi: 10.1186/1742-4933-4-2

    131. Verdonk R C, Haagsma E B, Van Den Berg A P, et al. 2006. Inflammatory bowel disease after liver trans-plantation: a role for cytomegalovirus infection. Scand J Gastroenterol, 41: 205-211.
        doi: 10.1080/00365520500206293

    132. Vescovini R, Biasini C, Fagnoni F F, et al. 2007. Massive load of functional effector CD4+ and CD8+ T cells against cytomegalovirus in very old subjects. J Immunol, 179: 4283-4291.
        doi: 10.4049/jimmunol.179.6.4283

    133. Vink C, Beuken E, Bruggeman C A. 2000. Complete DNA sequence of the rat cytomegalovirus genome. J Virol, 74: 7656-7665.
        doi: 10.1128/JVI.74.16.7656-7665.2000

    134. Vitale M, Castriconi R, Parolini S, et al. 1999. The leukocyte Ig-like receptor (LIR)-1 for the cytomega-lovirus UL18 protein displays a broad specificity for different HLA class Ⅰ alleles: analysis of LIR-1 + NK cell clones. Int Immunol, 11: 29-35.
        doi: 10.1093/intimm/11.1.29

    135. Voigt S, Mesci A, Ettinger J, et al. 2007. Cytomega-lovirus evasion of innate immunity by subversion of the NKR-P1B:Clr-b missing-self axis. Immunity, 26: 617-627.
        doi: 10.1016/j.immuni.2007.03.013

    136. Wagner C S, Ljunggren H G, Achour A. 2008. Immune modulation by the human cytomegalovirus-encoded molecule UL18, a mystery yet to be solved. J Immunol, 180: 19-24.
        doi: 10.4049/jimmunol.180.1.19

    137. Waller E C, Day E, Sissons J G, et al. 2008. Dynamics of T cell memory in human cytomegalovirus infection. Med Microbiol Immunol, 197: 83-96.
        doi: 10.1007/s00430-008-0082-5

    138. Weller T H, Hanshaw J B, Scott D E. 1960. Serological differentiation of viruses responsible for cytomegalic inclusion disease. Virology, 12: 130-132.
        doi: 10.1016/0042-6822(60)90156-2

    139. Wiertz E J, Jones T R, Sun L, et al. 1996. The human cytomegalovirus US11 gene product dislocates MHC class Ⅰ heavy chains from the endoplasmic reticulum to the cytosol. Cell, 84: 769-779.
        doi: 10.1016/S0092-8674(00)81054-5

    140. Woolhouse M E, Webster J P, Domingo E, et al. 2002. Biological and biomedical implications of the co-evolution of pathogens and their hosts. Nat Genet, 32: 569-577.
        doi: 10.1038/ng1202-569

    141. Yi L, Lin J Y, Gao Y, et al. 2008. Detection of human cytomegalovirus in the atherosclerotic cerebral arteries in han population in china. Acta Virol, 52: 99-106.

    142. Ziemann M, Krueger S, Maier A B, et al. 2007. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion, 47: 1972-1983.
        doi: 10.1111/trf.2007.47.issue-11

  • 加载中

Article Metrics

Article views(4673) PDF downloads(15) Cited by()

Related
Proportional views

    Pathogenetic Consequences of Cytomegalovirus-Host Co-evolution

      Corresponding author: Fenyong Liu, liu_fy@uclink4.berkeley.edu
    • Division of Infectious Diseases, School of Public Health, University of California, Berkeley, CA 94720, USA
    Fund Project:  This work was, in part, supported by US Public Health Service DE014145This work was, in part, supported by US Public Health Service AI041927This work was, in part, supported by US Public Health Service AI050468This work was, in part, supported by US Public Health Service DE016813

    Abstract: Co-evolution has been shown to result in an adaptive reciprocal modification in the respective behaviors of interacting populations over time. In the case of host-parasite co-evolution, the adaptive behavior is most evident from the reciprocal change in fitness of host and parasite-manifested in terms of pathogen survival versus host resistance. Cytomegaloviruses and their hosts represent a pairing of populations that has co-evolved over hundreds of years. This review explores the pathogenetic consequences emerging from the behavioral changes caused by co-evolutionary forces on the virus and its host.